A team at the La Jolla, CA-based Sanford-Burnham Medical Research Institute has developed a compound called SMIP004 that causes a decrease in the number of androgen receptors--proteins located in prostate cancer cells that are activated by testosterone. The compound could offer a promising new treatment against castration-resistant prostate cancer cells, which grow and proliferate by finding alternative means of spurring the development of androgen. More